NBIX
Mild doesn’t mean harmless
Neurocrine Biosciences took the mic on Monday and reminded everyone that “mild” tardive dyskinesia can still be a pretty big pain in the face, socially, emotionally, and physically. In a clinician survey, 90% of patients with mild TD experienced some kind of impairment, which is a nice little reality check for anyone who thought the label sounded too soft to matter.
INGREZZA gets the spotlight
The company said that after patients started INGREZZA (valbenazine), 96% of those with mild TD showed clinician-reported improvement in uncontrolled movements. Even better for the stopwatch crowd: 86% of those improved within four weeks. That’s the kind of timeline that can make a therapy feel less like a maybe and more like a real-world habit.
Why investors should care
Here’s the investor angle: Neurocrine isn’t just selling a drug, it’s selling the argument that TD has a meaningful functional burden even when it’s not at the severe end of the spectrum. And when a treatment shows quick improvement tied to independence, work, and daily living, that’s the sort of messaging that can help keep the prescription engine humming.
Big picture
This doesn’t rewrite the Neurocrine story overnight, but it does add another tile to the INGREZZA mosaic: broader need, visible benefit, and a reminder that “mild” in medicine often means “still annoying enough to pay attention to.”